B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer

Cancer Cell International
Ling WangFu-Biao Kang

Abstract

The expression of the immunoregulatory protein B7-H4 has been reported in many types of cancer, including breast cancer. However, its role in triple-negative breast cancer (TNBC), especially its correlation with patients' prognosis and chemoresistance remains unclear. The expression of B7-H4 in TNBC tissues and cell lines were measured with Real-Time PCR and western blotting. 65 cases of TNBC tissue samples and adjacent non-tumor tissue samples were analyzed by immunochemistry to demonstrate the correlation between the B7-H4 expression and clinicopathological characteristics. In vitro studies assessed mAb MIH43 alone and in combination with transfecting B7-H4 siRNA on the growth of chemosensitive and chemoresistant TNBC cell lines by CCK-8 and apoptotic enzyme-linked immunosorbent assay (ELISA). B7-H4 expression was detected positive in 59 of 65 (90.8%) different stage TNBC patients, especially in the samples of recurrence TNBC patients after receiving neoadjuvant chemotherapy treatment. Survival curves showed that patients with B7-H4 overexpression had significantly shorter survival and recurrence time than those with low B7-H4 expression (p < 0.005). Univariate and multivariate COX regression analysis demonstrated that B7-H4 ...Continue Reading

References

Jun 24, 2003·Immunity·Gabriel L SicaLieping Chen
Jun 24, 2003·Immunity·Durbaka V R PrasadChen Dong
Aug 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Xingxing ZangJames P Allison
Oct 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·In-Hak ChoiLieping Chen
Mar 18, 2005·Annual Review of Immunology·Rebecca J GreenwaldArlene H Sharpe
Apr 7, 2007·Journal of Immunotherapy·Dallas B Flies, Lieping Chen
May 12, 2009·Immunological Reviews·Kyung H Yi, Lieping Chen
Jun 25, 2009·Cancer Research·Ann F Chambers
Mar 8, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dagmar QuandtBarbara Seliger
May 3, 2011·Nature Cell Biology·Subbareddy MaddikaJunjie Chen
Aug 23, 2012·Gynecologic Oncology·Janelle M FauciDonald J Buchsbaum
Mar 5, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yael M AbadiXingxing Zang
Jul 23, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ming LiangShibo Sun
Sep 10, 2013·International Journal of Cancer. Journal International Du Cancer·Ling WangBao-En Shan
Mar 25, 2014·Gynecologic Oncology·Jenessa B SmithDaniel J Powell
Sep 28, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ninu MaskeyGuifang Yang
Dec 21, 2014·Cancer Immunology Research·Ramtin RahbarPamela S Ohashi
Apr 9, 2015·Molecular Pharmaceutics·Steven R LeongAndrew G Polson
Sep 29, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ling WangBao-En Shan
Dec 9, 2015·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·James ClarkBastiaan Hoogendoorn
Mar 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Saya H EbbesenScott W Lowe
Mar 5, 2016·Oncoimmunology·Ramtin Rahbar, Pamela S Ohashi
Mar 24, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu YaoLiangfu Zhou
May 4, 2016·Oncoimmunology·Alan Serrels, Margaret C Frame
Oct 19, 2016·Nature Reviews. Clinical Oncology·Giampaolo BianchiniLuca Gianni
Nov 3, 2016·Nature Reviews. Clinical Oncology·Maurizio Zanetti
Oct 25, 2016·Human Pathology·Li LiangJinsong Liu
Jul 8, 2016·Cancer Immunology, Immunotherapy : CII·Lei WuZhi-Jun Sun
Jul 15, 2016·The Oncologist·Valerie LeeLuis A Diaz
Aug 27, 2016·Annals of Translational Medicine·Marinos Tsiatas, Petros Grivas
Sep 2, 2016·Therapeutic Advances in Medical Oncology·Poornima Saha, Rita Nanda
Sep 17, 2016·Oncotarget·Hannah NipShahana Majid
Oct 30, 2016·Anticancer Research·Ammar SukariLawrence G Lum

❮ Previous
Next ❯

Citations

Feb 6, 2020·International Journal of Cancer. Journal International Du Cancer·De ZengGuo-Jun Zhang
Nov 18, 2019·Cellular Immunology·Jia-Yu Wang, Wei-Peng Wang
Jul 31, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Guojuan Miao, Xiuhong Sun
Jul 27, 2021·Frontiers in Molecular Biosciences·Dongli CaiLiping Jin

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
transfection
PCR
ELISA
xenograft

Software Mentioned

SPSS

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.